Table 4.

Summary of changes in laboratory-evaluated biochemical parameters during the 52-week treatment period

	Omalizumab (n =68)		Placebo (n =69)
	Mean change from baseline at 52 weeks	Median at baseline (range)	Mean change from baseline at 52 weeks	Median at baseline (range)
Parameter (units)
Haemoglobin (g/dL)	−0.1	13.5 (11.3–16.0)	−0.1	13.5 (9.8–17.8)
Eosinophils (%)	−1.6	5.6 (1.4–26.5)	−0.4	5.6 (0.9–21.9)
Alanine aminotransferase, ALT (U/L)	−0.3	15.0 (9–44)	−0.9	14.0 (7–78)
Alkaline phosphatase (serum), ALP (U/L)	−38.5	456.5 (92–1.238)	−40.0	305 (100–1.002)
Aspartate aminotransferase, AST (U/L)	−0.7	22.5 (13–44)	−0.3	22.0 (13–47)